A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

76 citing papers in PubMed, 6 syntheses or guidelines pooled it.

1. Role of SH2B3 R262W gene polymorphism and risk of coronary heart disease: A PRISMA-compliant meta-analysis.Medicine · 2018
   Pooled it
2. Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants that contribute to lipid levels and coronary artery disease.Nature genetics · 2017
   Pooled it
3. Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.Circulation research · 2017
   Pooled it
4. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.Nature genetics · 2015
   Pooled it
5. Meta-analyses of four eosinophil related gene variants in coronary heart disease.Journal of thrombosis and thrombolysis · 2013
   Pooled it
6. Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls.PLoS pathogens · 2013
   Pooled it
7. Associations Between Gene Variants of Lipid-Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke.Journal of the American Heart Association · 2024
   Trial
8. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.Journal of atherosclerosis and thrombosis · 2022
   Trial
9. PCSK9 is a critical regulator of the innate immune response and septic shock outcome.Science translational medicine · 2014
   Trial
10. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.The Journal of clinical endocrinology and metabolism · 2010
    Trial
11. Clinical effect of proprotein convertase subtilisin/kexin type 9 inhibition in patients undergoing coronary artery bypass surgery.JTCVS open · 2026
    Article
12. Deep analysis of the major histocompatibility complex genetic associations using covariate analysis and haploblocks unravels new mechanisms for the molecular etiology of Elite Control in AIDS.BMC immunology · 2025
    Article
13. Small Interfering RNA (siRNA) in Dyslipidemia: A Systematic Review on Safety and Efficacy of siRNA.Journal of experimental pharmacology · 2025
    Review
14. Evolocumab Treatment in Dyslipidemic Patients Undergoing Coronary Artery Bypass Grafting: One-Year Safety and Efficacy Results.Journal of clinical medicine · 2024
    Article
15. Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed whole-genome sequencing study.American journal of human genetics · 2023
    Article
16. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
17. Acute Coronary Syndrome: Disparities of Pathophysiology and Mortality with and without Peripheral Artery Disease.Journal of personalized medicine · 2023
    Review
18. Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population.Cell genomics · 2023
    Article
19. TheFrontiers in immunology · 2023
    Article
20. The dawn of a new era of targeted lipid-lowering therapies.European heart journal · 2022
    Review

16 more citing papers are in PubMed but not listed here.

Corrections and comments

• Comment on
  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.2006

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as